StreetInsider.com News Articles

Form 6-K Clearmind Medicine Inc. For: Oct 27

Tue, 27 Oct 2026 08:24:00 -0400

si-local-file:///var/storage/secattach/20261027/27237293.html

Clearmind completes patient recruitment for AUD drug trial cohort

Tue, 27 Oct 2026 08:22:10 -0400

Clearmind Medicine Inc. (Nasdaq: CMND) announced it has completed patient recruitment for the first cohort of Part B of its Phase I/IIa clinical trial evaluating CMND-100 in patients with moderate-to-severe alcohol use disorder (AUD), according to a press release.

Part B represents the first evaluation of CMND-100 in AUD patients, following the completion of Part A in healthy volunteers. The trial's Part B consists of two sequential single-dose ascending cohorts of 80 mg and 160 mg, each enrolling six patients. The cohorts are designed to assess safety, tolerability, pharmacokinetics, and early signals of clinical efficacy, including potential reductions in alcohol craving.

The

Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial

Tue, 27 Oct 2026 08:22:00 -0400

Milestone advances Clearmind’s clinical program as the company continues to develop CMND‑100 as a potential novel therapeutic candidate for alcohol use disorder

Vancouver, Canada, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the completion of patient recruitment for the first segment of Part B of its ongoing Phase I/IIa clinical trial evaluating CMND-100 in patients with moderate-to-severe Alcohol Use Disorder (AUD).

Part B marks

Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial

Tue, 27 Oct 2026 08:22:00 -0400

Milestone advances Clearmind’s clinical program as the company continues to develop CMND‑100 as a potential novel therapeutic candidate for alcohol use disorder

Part B marks

Form 6-K Clearmind Medicine Inc. For: Oct 16

Fri, 16 Oct 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20261016/27197907.html

Form 6-K Clearmind Medicine Inc. For: Oct 13

Tue, 13 Oct 2026 06:16:00 -0400

si-local-file:///var/storage/secattach/20261013/27176466.html

Charging Robotics unveils wireless EV charging platform for autonomo

Mon, 12 Oct 2026 07:56:30 -0400

Charging Robotics Ltd., a 51%-owned subsidiary of Clearmind Medicine Inc. (NASDAQ: CMND), has launched a wireless electric vehicle charging platform designed for robotaxis, autonomous fleets and automated parking facilities, according to a press release.

The platform uses resonant inductive power transfer technology to deliver electricity across an air gap without physical connectors, eliminating the need for manual cable connections, robotic arms or dedicated docking maneuvers. The system is designed to deliver up to 10 kW of charging power at up to 95% efficiency under specified operating conditions.

For automated parking facilities, the technology allows electric vehicles to charge while stored in areas

Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets

Mon, 12 Oct 2026 07:55:00 -0400

Vancouver, Canada, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that Charging Robotics Ltd. (“Charging Robotics”), its 51%-owned subsidiary, has launched the next generation of its autonomous vehicle charging platform, designed for robotaxis, autonomous fleets and automated parking facilities.

The platform uses resonant inductive power transfer technology to transfer electricity across an air gap without physical connectors. The system is designed to deliver

Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets

Mon, 12 Oct 2026 07:55:00 -0400

The platform uses resonant inductive power transfer technology to transfer electricity across an air gap without physical connectors. The system is designed to deliver

Form 6-K Clearmind Medicine Inc. For: Oct 08

Thu, 08 Oct 2026 07:56:00 -0400

si-local-file:///var/storage/secattach/20261008/27163799.html

Clearmind patent application for dyskinesia treatment published in Japan

Thu, 08 Oct 2026 07:34:26 -0400

Clearmind Medicine Inc. (Nasdaq: CMND) announced the publication of a patent application in Japan covering compositions and methods for treating dyskinesia, a neurological movement disorder characterized by involuntary movements.

The published application covers the use of 3-Methylmethcathinone (3-MMC) for preventing, treating, or reducing dyskinesia symptoms, including pharmaceutical compositions containing 3-MMC. The application also includes claims for combinations of 3-MMC with Palmitoylethanolamide (PEA), a compound described as having anti-inflammatory and neuroprotective properties.

The patent application is part of an ongoing collaboration between Clearmind and NeuroThera Labs Inc. (TSXV: NTLX), through which PEA technology is integrated into Clearmind's therapeutic programs.

"The publication of the patent

Clearmind patent application for dyskinesia treatment published in Japan

Thu, 08 Oct 2026 07:34:26 -0400

The patent application is part of an ongoing collaboration between Clearmind and NeuroThera Labs Inc. (TSXV: NTLX), through which PEA technology is integrated into Clearmind's therapeutic programs.

"The publication of the patent

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder

Thu, 08 Oct 2026 07:32:00 -0400

Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA)

Vancouver, Canada, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the publication of a patent application in Japan covering novel compositions and methods for treating dyskinesia, a neurological movement disorder characterized by involuntary movements. The published patent application covers the use of 3-Methylmethcathinone (“3-MMC”) for preventing, treating, or reducing dyskinesia symptoms, including pharmaceutical

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder

Thu, 08 Oct 2026 07:32:00 -0400

Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA)

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder

Thu, 08 Oct 2026 07:32:00 -0400

Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA)

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder

Thu, 08 Oct 2026 07:32:00 -0400

Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA)

Form 6-K Clearmind Medicine Inc. For: Oct 07

Wed, 07 Oct 2026 08:41:00 -0400

si-local-file:///var/storage/secattach/20261007/27158610.html

Clearmind submits psychedelic therapy recommendations to FDA

Wed, 07 Oct 2026 08:41:00 -0400

Clearmind Medicine Inc. (NASDAQ: CMND), a clinical-stage biopharmaceutical company, submitted recommendations to the U.S. Food and Drug Administration in response to the agency's public hearing on the potential future therapeutic use of psychedelic drugs, according to a press release.

The submission, filed under FDA Docket No. FDA-2026-N-7542, focuses on non-hallucinogenic psychedelic-derived compounds the company refers to as neuroplastogens, with a particular focus on alcohol use disorder. Clearmind recommends the FDA consider new guidance for self-administration and at-home therapies, streamlined regulatory pathways, expanded clinical trial access, and use of Breakthrough Designation.

The company also called for research collaborations with the U.S. Department of

Clearmind submits psychedelic therapy recommendations to FDA

Wed, 07 Oct 2026 08:41:00 -0400

The company also called for research collaborations with the U.S. Department of

Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA

Wed, 07 Oct 2026 08:40:00 -0400

Company Calls for Consideration of New Regulatory Pathways and Cost Saving of Non-Hallucinogenic Neuroplastogens for Alcohol Use Disorder

Vancouver, Canada, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced that it has submitted recommendations to the U.S. Food and Drug Administration (“FDA”) in response to the agency’s public hearing and request for comments on “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs.”

Under FDA Docket No.

Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA

Wed, 07 Oct 2026 08:40:00 -0400

Company Calls for Consideration of New Regulatory Pathways and Cost Saving of Non-Hallucinogenic Neuroplastogens for Alcohol Use Disorder

Under FDA Docket No.

Form 6-K Clearmind Medicine Inc. For: Sep 30

Wed, 30 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260930/27129019.html

NeuroThera files 3 U.S. patents on LSD, ketamine, ibogaine combos

Wed, 23 Sep 2026 08:35:46 -0400

SciSparc Ltd. (NASDAQ: SPRC), through its subsidiary NeuroThera Labs Inc. (TSXV: NTLX), announced the publication of three U.S. patent applications covering novel combinations of LSD, ketamine, and ibogaine with N-acylethanolamines, including palmitoylethanolamide (PEA), as part of an ongoing collaboration with Clearmind Medicine Inc. (NASDAQ: CMND).

The applications cover potential therapeutic uses for mental health disorders including depression and post-traumatic stress disorder, as well as pain and substance use disorders.

The new filings follow a previously announced U.S. patent application from the same collaboration covering the combination of MDMA and N-acylethanolamines for potential treatment of PTSD, anxiety, and eating disorders.

NeuroThera and Clearmind stated

NeuroThera files 3 U.S. patents on LSD, ketamine, ibogaine combos

Wed, 23 Sep 2026 08:35:46 -0400

The applications cover potential therapeutic uses for mental health disorders including depression and post-traumatic stress disorder, as well as pain and substance use disorders.

NeuroThera and Clearmind stated

NeuroThera files 3 U.S. patents on LSD, ketamine, ibogaine combos

Wed, 23 Sep 2026 08:35:46 -0400

The applications cover potential therapeutic uses for mental health disorders including depression and post-traumatic stress disorder, as well as pain and substance use disorders.

NeuroThera and Clearmind stated